Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Core Insights - Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders [3] - The company will participate in The Citizens Life Sciences Conference on March 10-11, 2026, with a presentation scheduled for March 10 at 9:35 AM ET [2] - Minerva is initiating a confirmatory Phase 3 trial with roluperidone aimed at treating negative symptoms of schizophrenia [3] Company Information - Minerva Neurosciences, Inc. is dedicated to developing product candidates specifically for CNS diseases [3] - The company’s Executive Chairman & CEO, Remy Luthringer, will represent Minerva at the upcoming conference [1] - A replay of the conference presentation will be available for ninety days on the company's Investors & Media Events webpage [2]